Reply: Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan

被引：0
|
作者：
G Chong
D Cunningham
机构：
[1] Royal Marsden Hospital,
[2] G1 Cancer/Lymphoma Unit,undefined
来源：
British Journal of Cancer | 2006年 / 94卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：937 / 937
相关论文
共 50 条
  • [41] A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer
    Daniel J. Renouf
    Stephen Welch
    Malcolm J. Moore
    Monika K. Krzyzanowska
    Jennifer Knox
    Ronald Feld
    Geoffrey Liu
    Helen MacKay
    Jennifer Petronis
    Lisa Wang
    Eric Chen
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1339 - 1344
  • [42] CAPECITABINE AND IRINOTECAN (CAPIRI) AS FIRST -LINE TREATMENT FOR PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Bounedjar, A.
    Smail, F.
    ANNALS OF ONCOLOGY, 2010, 21 : 67 - 68
  • [43] Is there a role for mitomycin C in metastatic colorectal cancer?
    Dimou, Anastasios
    Syrigos, Kostas N.
    Saif, Muhammad Wasif
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (06) : 723 - 735
  • [44] Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
    Rougier, P
    Van Cutsem, E
    Bajetta, E
    Niederle, N
    Possinger, K
    Labianca, R
    Navarro, M
    Morant, R
    Bleiberg, H
    Wils, J
    Awad, L
    Herait, P
    Jacques, C
    LANCET, 1998, 352 (9138): : 1407 - 1412
  • [45] Sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC)
    Cupini, S.
    Bursi, S.
    Masi, G.
    Loupakis, F.
    Barbara, C.
    Barletta, M. T.
    Baldi, G. G.
    Vasile, E.
    Fornaro, L.
    Petrini, I.
    Allegrini, G.
    Antonuzzo, A.
    Di Marsico, R.
    Andreuccetti, M.
    Ricci, S.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 6 - 6
  • [46] Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer
    Douillard, JY
    ONCOLOGY-NEW YORK, 2000, 14 (12): : 51 - 55
  • [47] Capecitabine in combination with mitomycin C as third line chemotherapy in patients with advanced colorectal cancer
    Ritorto, G.
    Fanchini, L.
    Racca, P.
    Evangelista, W.
    Volpatto, R.
    Angelini, F.
    Ciuffreda, L.
    Ottaviani, D.
    Bertetto, O.
    ANNALS OF ONCOLOGY, 2005, 16 : 46 - 46
  • [48] Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure
    Alkis, N.
    Demirci, U.
    Benekli, M.
    Yilmaz, U.
    Isikdogan, A.
    Sevinc, A.
    Ozdemir, N. Y.
    Koca, D.
    Yetisyigit, T.
    Kaplan, M. A.
    Uncu, D.
    Unek, T.
    Gumus, M.
    JOURNAL OF BUON, 2011, 16 (01): : 80 - 83
  • [49] Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer
    Massacesi, Cristian
    La Cesa, Annalisa
    Marcucci, Fabiana
    Pilone, Alberta
    Rocchi, Marco B. L.
    Zepponi, Laura
    Santini, Daniele
    Tonini, Giuseppe
    Burattini, Luciano
    ONCOLOGY, 2006, 70 (04) : 294 - 300
  • [50] Combined oxaliplatin, irinotecan and fluorouracil as a rescue regimen for heavily pretreated metastatic colorectal cancer patients
    Dos Santos Fernandes, G.
    Braghiroli, M. I.
    Artioli, M.
    Paterlini Ana, C.
    Teixeira, M. C.
    Gumz, B.
    Costa, F.
    Hoff, P.
    ANNALS OF ONCOLOGY, 2016, 27 : 45 - 46
12345